Company Profile

PPD Inc is a United States-based company. The Company is engaged in providing clinical development and laboratory services to pharmaceutical, and biotechnology industries. It provides solutions such as early development, product development and consulting, site and patient centric solutions. It also provides laboratories such as bioanalytical lab, biomarker lab, central lab, and vaccine science lab.

Employees

26,000

Sector

Biotechnology & Medical Research

More about the company

20/04/22	PPD, Inc. acquired Vigi Medsafe Private Limited from the shareholders of Vigi Medsafe .	CI
08/01/22	Chilean court rejects appeal to stop tender for new lithium contracts	RE
13/12/21	PPD, Inc.(NasdaqGS:PPD) dropped from S&P TMI Index	CI
13/12/21	PPD, Inc.(NasdaqGS:PPD) dropped from S&P Global BMI Index	CI
08/12/21	PPD, Inc.(NasdaqGS:PPD) dropped from NASDAQ Composite Index	CI
08/12/21	Thermo Fisher Scientific Inc. completed the acquisition of PPD, Inc. from Hellman & Friedman Capital Partners VII, L.P. managed by Hellman & Friedman LLC, Carlyle Partners VI, L.P. managed by The Carlyle Group Inc. (NasdaqGS:CG) and others.	CI
03/12/21	UK Regulator Clears Thermo Fisher's Acquisition of PPD	MT
03/12/21	British Competition Watchdog Clears Thermo Fisher's $21 Billion PPD Purchase	MT
03/12/21	FTSE 100 to Open Higher	DJ
03/12/21	UK Regulator Won't Refer Thermo Fisher's Acquisition of PPD for Further Review	DJ
04/11/21	EU to Decide on Thermo Fisher's $21 Billion PPD Purchase by Dec. 7	MT
03/11/21	EU antitrust decision on Thermo Fisher's PPD deal due by Dec. 7	RE
28/10/21	PPD, Inc., Q3 2021 Earnings Call, Oct 28, 2021

08/06/21	Analyst recommendations: Amgen, Biogen, Halfords, J Sainsbury, Uber...
08/06/21	Correction: Mizuho Securities Maintains Price Target for PPD at $47.50, Reiterates Neutral Rating	MT
08/06/21	PPD : Mizuho Securities Adjusts PPD Price Target to $38 From $47.50, Maintains Neutral Rating	MT
29/04/21	PPD : JPMorgan Downgrades PPD to Neutral from Overweight, Lifts PT to $48 From $42	MT
21/04/21	PPD : Jefferies Downgrades PPD to Hold Rating From Buy, Lifts PT to $47.50 From $43	MT

09/12/21	PPD : Thermo Fisher Scientific Completes Acquisition of PPD, Inc - Form 8-K	PU
09/12/21	PPD, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events (form 8-K)	AQ
08/12/21	PPD Named to ‘Best Workplaces in Greater China’ for Second Consecutive Year	BU
03/12/21	PPD Named ‘Best Vaccine CRO of the Year’ in Asia-Pacific	BU
23/11/21	PPD Wins Multiple Awards at Clinical Researcher of the Year Competition	BU

17/04/21	PUMP / DUMP #7
16/04/21	EN DIRECT DES MARCHES : L'Oréal, FDJ, Fnac Darty, HelloFresh, Daimler, GSK, Scor, Thermo Fisher, Alcoa...
16/04/21	La croissance chinoise s'invite chez les sorcières
16/04/21	PPD : Thermo Fisher übernimmt Auftragsforscher PPD für 21 Mrd Dollar
15/04/21	Dpa-AFX-Überblick: UNTERNEHMEN vom 15.04.2021 - 15.15 Uhr

Manager	Title	Age	Since
Brainard Hartman ADM	Chief Administrative Officer	62	01/07/2001
Rob Petrie CTO	Chief Tech/Sci/R&D Officer	-	01/01/1998
Karen Kaucic CTO	Chief Tech/Sci/R&D Officer	66	-

PPD, Inc. Stock

Stocks

PPD

US69355F1021

Biotechnology & Medical Research

Latest news : PPD, Inc.

Analysts' recommendations: PPD, Inc.

Press Releases: PPD, Inc.

News in other languages: PPD, Inc.

Quotes and Performance

Managers and Directors: PPD, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Director	Title	Age	Since
Michael Boxer BRD	Director/Board Member	64	08/12/2021
Anthony Smith BRD	Director/Board Member	64	08/12/2021
Maura A. Spellman BRD	Director/Board Member	-	08/12/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/12/21	David Johnston	Issuer sale	Chairperson	738,271	0.2101%
8/12/21	Christopher Fikry	Issuer sale	Executive/Senior Manager	622,274	0.1771%
8/12/21	David Simmons	Issuer sale	Chief Executive Officer	6,902,583	1.9643%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PPD, INC.	-0.06%	+0.21%	-	-	16.61B
LONZA GROUP AG	-0.49%	-4.01%	-0.84%	+2.28%	48.71B
REVOLUTION MEDICINES, INC.	-3.10%	-1.94%	+370.99%	+572.60%	38.35B
BEONE MEDICINES AG	-0.46%	+2.18%	+5.44%	+61.01%	34.53B
IQVIA HOLDINGS INC.	-1.14%	-1.76%	+26.94%	-9.93%	34.03B
CELLTRION, INC.	-1.82%	-1.43%	+0.52%	+31.85%	26.77B
ASCENDIS PHARMA A/S	-3.54%	-5.08%	-	-	15.64B
MEDPACE HOLDINGS, INC.	-1.82%	-0.43%	+69.28%	+113.82%	15.08B
EUROFINS SCIENTIFIC SE	+1.17%	+2.30%	+15.87%	+18.26%	14.18B
ICON PUBLIC LIMITED COMPANY	-2.25%	+0.05%	+15.77%	-32.83%	12.73B
Average	-1.35%	-1.12%	+63.00%	+94.63%	26.67B
Weighted average by Cap.	-1.33%	-1.44%	+74.77%	+116.99%